Bacillus subtilis/Enterococcus faecium/mosapride

Drug Profile

Bacillus subtilis/Enterococcus faecium/mosapride

Alternative Names: HCP 0613; Medilac/mosapride; Medirac/mosapride; Mosapride/Bacillus subtilis/Enterococcus faecium; Mosapride/Bacillus subtilis/Streptococcus faecium; Mosapride/Enterococcus faecium/Bacillus subtilis; Mosapride/Medilac; Mosapride/Medirac; Mosapride/probiotics; Probiotics/mosapride

Latest Information Update: 17 Aug 2015

Price : $50

At a glance

  • Originator Hanmi Pharmaceutical
  • Class Bacteria; Benzamides; Gastrokinetics; Morpholines; Probiotics; Small molecules
  • Mechanism of Action Bacteria replacements; Serotonin 4 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Irritable bowel syndrome

Most Recent Events

  • 31 Jan 2012 Bacillus subtilis/Enterococcus faecium/mosapride is available for licensing
  • 01 May 2011 Phase-II clinical trials in Irritable bowel syndrome in South Korea (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top